The baseline hemoglobin level is a positive biomarker for immunotherapy response and can improve the predictability of tumor mutation burden for immunotherapy response in cancer
The HGB measure has the potential clinical value as a novel biomarker of immunotherapy response that is easily accessible from clinically routine examination. The combination of TMB and HGB measures have better predictive performance for immunotherapy response than TMB.
Authors
- Li Zhao (ORCID: https://orcid.org/0000-0001-9389-3474)
- Xiaosheng Wang (ORCID: https://orcid.org/0000-0002-7199-7093)
- Tong Ren (ORCID: https://orcid.org/0000-0003-2967-5047)
- Yin He (ORCID: https://orcid.org/0000-0002-5490-2611)
- Chengfei Ji
Institutions
- China Pharmaceutical University (CN)
- Xuzhou Medical College (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-10-02
- DOI
- https://doi.org/10.3389/fphar.2024.1456833
- Citations
- 6
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.70